Mizuho raised the firm’s price target on BrightSpring Health (BTSG) to $52 from $50 and keeps an Outperform rating on the shares. The company’s investor day brought an “attractive” mid-double-digit adjusted EBITDA intermediate growth algorithm, the analyst tells investors in a research note. The firm sees more upside potential than downside risk to its new estimates given BrightSpring’s business diversification.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTSG:
- BrightSpring: Specialty Pharmacy Growth, Structural Tailwinds, and Upside to Long-Term EBITDA Targets Support Buy Rating
- BrightSpring: Diversified Growth and Attractive Valuation Underpin Buy Rating
- BrightSpring (BTSG): Gaining Share in Lower-Cost Post-Acute Care with Strong Segment Momentum and Margin Upside Supporting $55 Target
- BrightSpring Announces Secondary Offering and Share Repurchase Plan
- BrightSpring Health price target raised to $48 from $40 at Morgan Stanley